tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Critical Illness D016638 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Hematuria D006417 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Urticaria D014581 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Biliary Fistula D001658 13 associated lipids
Vasculitis D014657 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Alopecia D000505 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Stomatitis D013280 14 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
Testicular Diseases D013733 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Neutropenia D009503 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Down Syndrome D004314 18 associated lipids
Albuminuria D000419 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Ischemia D007511 18 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Harrison RK and Stein RL Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. 1990 Biochemistry pmid:1693856
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia. 1990 Life Sci. pmid:1698241
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Van Thiel DH et al. Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1721357
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Heitman J et al. FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1705713
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Francavilla A et al. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. 1991 Hepatology pmid:1712337
Aoki H [FK 506, a new immunosuppressant produced by a Streptomyces]. 1991 Nippon Rinsho pmid:1712403
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
DeFranco AL Signal transduction. Immunosuppressants at work. 1991 Nature pmid:1715515